We are transforming how cancer treatment decisions are made—moving beyond static and imperfect biomarkers to a new era of functional precision oncology.

Traditional cancer diagnostics rely on genetic or protein markers, which often fail to capture how a patient’s tumour actually behaves. Our proprietary platform directly measures DNA repair activity in tumour cells through real-time, multiplexed functional assays—essentially putting cancer cells through a “stress test” to reveal how different DNA repair pathways operate.

Our technology serves as a high-value research tool for pharmaceutical companies and CROs, accelerating the validation of DNA Damage Response (DDR) inhibitors and reducing clinical trial risk. These same functional insights will power companion diagnostics that enable oncologists to personalise treatment based on a tumour’s unique biology.

Our vision is simple yet profound: every cancer patient examined, diagnosed, and treated according to the real-time functional behaviour of their tumour—making personalised medicine not just a goal, but a measurable reality.

STRATISAL

Org chart

Teams

Offices

STRATISAL

Org chart

Teams

Offices

Related companies